Table 1.
Antiproliferative activities of all target compounds against different human cell lines
| Compd | IC50±SD (µM)a |
|||||
|---|---|---|---|---|---|---|
| A549 | Hela | MCF-7 | U937 | MGC-803 | HepG2 | |
| 4a | >5 | >5 | >5 | >5 | >5 | >5 |
| 4b | 3.635 ± 0.001 | 0.685 ± 0.002 | 0.551 ± 0.022 | 0.562 ± 0.020 | 0.202 ± 0.023 | 0.883 ± 0.041 |
| 4c | 0.202 ± 0.012 | 0.025 ± 0.001 | 0.254 ± 0.037 | 0.025 ± 0.001 | 0.0571 ± 0.006 | >5 |
| 4d | >5 | >5 | >5 | >5 | >5 | >5 |
| 4e | >5 | 0.101 ± 0.031 | 0.551 ± 0.014 | 0.123 ± 0.011 | 0.072 ± 0.002 | 1.385 ± 0.001 |
| 4f | >5 | >5 | >5 | >5 | >5 | >5 |
| 4g | 0.505 ± 0.010 | 0.072 ± 0.001 | 0.121 ± 0.012 | 0.456 ± 0.013 | 0.021 ± 0.007 | 0.199 ± 0.006 |
| 4h | 2.569 ± 0.159 | 2.493 ± 0.002 | 2.101 ± 0.003 | 0.606 ± 0.026 | 1.897 ± 0.001 | 5.976 ± 0.004 |
| 4i | >5 | >5 | >5 | >5 | >5 | >5 |
| 4j | >5 | >5 | >5 | >5 | >5 | >5 |
| 4k | >5 | 0.565 ± 0.012 | 0.441 ± 0.001 | 0.806 ± 0.024 | 0.166 ± 0.004 | 3.298 ± 0.007 |
| 4l | >5 | >5 | >5 | >5 | >5 | >5 |
| 4m | >5 | 0.925 ± 0.007 | 1.002 ± 0.007 | 0.710 ± 0.027 | 0.362 ± 0.123 | 1.407 ± 0.014 |
| 4n | 0.364 ± 0.003 | 0.042 ± 0.001 | 0.128 ± 0.004 | 0.031 ± 0.001 | 0.043 ± 0.001 | 0.116 ± 0.001 |
| 4o | >5 | >5 | 4.408 ± 0.043 | >5 | 3.301 ± 0.026 | >5 |
| 4p | >5 | >5 | >5 | >5 | >5 | >5 |
| 4q | >5 | >5 | >5 | >5 | >5 | >5 |
| 4r | >5 | >5 | >5 | >5 | >5 | >5 |
| 4s | >5 | >5 | >5 | >5 | >5 | >5 |
| 4t | 1.025 ± 0.064 | 0.203 ± 0.006 | 1.293 ± 0.007 | 0.125 ± 0.002 |
N.D.b |
1.063 ± 0.008 |
| CA-4 | 0.005 ± 0.001 | 0.008 ± 0.001 | 0.011 ± 0.001 | 0.0003 ± 0.001 | 0.002 ± 0.001 | 0.007 ± 0.001 |
aIC50 values are presented as the mean ± SD(standard deviation) from three separated experiments. bN. D.: not determined.